Tag Archives: multiple sclerosis

University of Geneva and Geneva University Hospitals researchers identified a DNA-binding factor that plays a role in triggering multiple sclerosis

GENEVA, 16-May-2018 — /EuropaWire/ — Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech. There is still no cure … Read the full press release

EBRD takes part in the US$ 51 million private placement of Mabion S.A.

Participation in private placement as a cornerstone investor EBRD participates in US$ 51m equivalent private placement of Mabion Mabion is leading biotechnology company in Poland EBRD to invest US$ 18 million (PLN 61.4 million) LONDON, 26-Mar-2018 — /EuropaWire/ — The EBRD … Read the full press release

European Medicines Agency: multiple sclerosis medicine Zinbryta will be voluntarily withdrawn from the market

Medicine to be voluntarily withdrawn from the market by the company LONDON, 06-Mar-2018 — /EuropaWire/ — The European Medicines Agency (EMA) has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders … Read the full press release

Novartis, Pear Therapeutics to work together towards developing new treatments for patients with schizophrenia and multiple sclerosis

Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics  Novartis continues to embrace emerging … Read the full press release

Technical University of Munich (TUM): Multiple sclerosis: Cholesterol crystals can trigger chronic inflammation that in turn impedes regeneration in the central nervous system

  MUNICH, 09-Jan-2018 — /EuropaWire/ — Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system, in which the body’s own immune cells attack the fatty, insulating myelin sheath surrounding nerve fibers. The regeneration of intact myelin … Read the full press release

World MS Day 2017: Merck launches multiple sclerosis (MS) care partner survey with IACO

Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Darmstadt, Germany, 31-May-2017 … Read the full press release

Merck presented new data on efficacy and safety for investigational Cladribine Tablets at the American Academy of Neurology (AAN)

Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo DARMSTADT, 02-May-2017 — /EuropaWire/ — Merck, a leading science and technology company, announced the presentation of new analyses of efficacy and safety data for … Read the full press release

TUM the only Germany institute involved and the second largest partner in the project “MultipleMS”

A large global new partnership called ‘MultipleMS’, coordinated by Karolinska Institute in Sweden, has been awarded 15 million euro from the European Commission in the Horizon2020 program to find novel and better treatments for Multiple Sclerosis (MS). In this project, … Read the full press release

Proximus received MS@Work 2015 Award by National Belgian Multiple Sclerosis League for employing people with Multiple Sclerosis

On 9 September, Proximus received the MS@Work 2015 Award. The Award was presented by the National Belgian Multiple Sclerosis League as recognition for the positive policy Proximus pursues with regard to employing people with Multiple Sclerosis (MS). BRUSSELS, 14-9-2015 — … Read the full press release

Novartis to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK)

Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release

Merck Serono expands availability of its RebiSmart device and web-based software platform MSdialog to people with MS in Spain, Greece, Hungary, Israel, Chile and Colombia

The new RebiSmart® injection device offers many new updates including wireless transmission of injection times and doses MSdialog™software is designed to more effectively engage people with MS and their health care providers with treatment adherence information and health related outcome reports … Read the full press release

LMU Dr. Klaus Dornmair and Prof. Jörg Prinz report for novel technique to fight tumors and to treat autoimmune diseases

16-8-2013 — /EuropaWire/ — Immunologists at LMU have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the … Read the full press release

US Federal Circuit Court invalidated patents asserted against Sandoz by Teva Pharmaceuticals in litigation over generic version of Copaxone

Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading … Read the full press release

VivaCell Spain and Aphios USA to develop novel class of compounds for Multiple sclerosis and CNS disorders

Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration and Commercialization Agreements with Aphios Corporation, USA, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central … Read the full press release